FDA approves supplemental NDAs for three type 2 diabetes medicines within the empagliflozin family to include landmark data in product labels

Luseogliflozin significantly reduced continuous glucose monitoring values and area under the curve

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?